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It is hypothesized that the intake of long-chain PUFA (LC-PUFA) throughout pregnancy could protect against pre-eclampsia, pregnancy-induced
hypertension or intra-uterine growth retardation, and is essential for optimal neural development. The objective of the present study was to system-
atically evaluate the effect of LC-PUFA supplementation of high-risk pregnant women’s diets on pregnancy outcomes and growth measures at
birth. We searched MEDLINE, EMBASE, CINAHL and the Cochrane Library through March 2006 and references in reviewed articles for ran-
domized controlled trials (RCT) comparing LC-PUFA supplementation with placebo or no supplementation in women with high-risk pregnancies.
We found no evidence that supplementation influenced the duration of pregnancy or the percentage of preterm deliveries ,37 weeks of gestation.
However, compared with controls, supplementation was associated with a significantly lower rate of early preterm delivery (,34 weeks of ges-
tation) (two RCT; n 291; relative risk 0·39 (95 % CI 0·18, 0·84)). There was no significant difference in the infant birth weight, the rate of low birth
weight (,2500 g or ,10th percentile) and the recurrence of intra-uterine growth retardation. Other pregnancy outcomes (for example, the rate of
pregnancy-induced hypertension, the rate of pre-eclampsia and the rate of Caesarean section) were also similar in both groups. In conclusion, the
present data suggest that supplementation with n-3 LC-PUFA in women with high-risk pregnancies reduced the risk of early preterm delivery in
the fatty acid-supplemented group compared with the placebo group, while no other effects on pregnancy outcomes were detected.
Polyunsaturated fatty acids: Fatty acids: High-risk pregnancy
Numerous studies reveal that long-chain PUFA (LC-PUFA) bio-
logical systems have the potential to influence maternal health
during pregnancy as well as fetal and child health1. Children
delivered at term receive an important supply of n-3 fatty
acids, especially in the third trimester of pregnancy. This
supply is essential for optimal fetal growth and neurodevelop-
ment2 – 4. When the gestational period is shortened, a child deliv-
ered prematurely receives less exposure to fatty acids. It has been
suggested that imbalance between n-3 and n-6 fatty acids may be
associated with disturbances in the production of PG (prostacy-
clin and thromboxane) which are responsible for placental blood
flow (indispensable for normal fetus growth and development)
and participate in the initiation of labour5. Thus, LC-PUFA sup-
plementation may decrease the risk of certain pregnancy compli-
cations, particularly pre-eclampsia, pregnancy-induced
hypertension (PIH), intra-uterine growth retardation (IUGR)
and preterm delivery (PD).
Recently, we published the results of a meta-analysis6 of six
randomized controlled trials (RCT) showing that n-3 LC-
PUFA supplementation during low-risk pregnancy may
enhance the duration of pregnancy and head circumference,
although the mean effect size was small. We found no
additional benefits for a number of other maternal and child
outcomes such as the percentage of PD, the rate of low birth
weight, the risk of pre-eclampsia and the risk of eclampsia.
The present meta-analysis was undertaken to investigate the
safety and efficacy of LC-PUFA in modulating various pregnancy
outcomes and growth parameters at birth in high-risk pregnancies.
Material and methods
Criteria for inclusion of studies
Studies included in the present review had to be RCT or quasi-
RCT comparing LC-PUFA supplementation with placebo or
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no supplementation in high-risk pregnant women. After an
initial assessment of the reviewed trials, we decided to focus
on pregnancy complications and growth measures at birth.
Additionally, we extracted all data related to adverse events.
Trials with healthy pregnant women in twin pregnancies
and/or with only biochemical outcomes were not included.
Search strategy to identify studies
The search strategy included the use of a validated filter for
identifying RCT7, which was combined with a topic-specific
strategy using PubMed’s MeSH terms related to the exposure
and its sources, for example, ‘FA’ or ‘omega’ or ‘n-6’ or ‘n-3’
or ‘eicosapentaenoic acid’ or ‘EPA’ or ‘docosahexaenoic acid’
or ‘DHA’ or ‘arachidonic acid’ or ‘LC-PUFA’ or ‘long-chain
FA’ or ‘essential FA’ or ‘fish oil’, and relevant population
terms, for example, ‘high risk pregnancy’ or ‘gestational
hypertension’. We performed a computerized literature
search of MEDLINE (from 1966 to March 2006), EMBASE
(from 1980 to March 2006), CINAHL (the Cumulative
Index to Nursing and Allied Health) (from 1982 to March
2006) and the Cochrane Library (issue 2, 2005). We sup-
plemented this search by examining published reviews and
position papers. References in reviewed articles constituted
additional sources. We imposed no limit with respect to the
language of publications, but certain publication types (for
example, letters to the editor, abstracts, proceedings from
scientific meetings) were excluded.
Methods of the review
Trial selection. One reviewer (A. H.) initially screened the
title, abstract and keywords of every record identified by the
search strategy; this reviewer then retrieved the full text for
potentially relevant studies and for trials where the relevance
was unclear. Two reviewers (A. H. and H. S.) independently
applied the inclusion criteria to each potentially relevant
trial to determine its eligibility. When differences in opinion
existed, they were resolved by discussion.
Quality assessment of trials. Two reviewers (A. H. and
H. S.) independently, but without being blinded to the authors
or journal, assessed the quality of the studies that met the
inclusion criteria. The following strategies associated with
good-quality studies were assessed: generation of allocation
sequences and allocation concealment; blinding of investi-
gators, participants, outcome assessors, and data analysis
(yes, no, or not reported); intention-to-treat analysis (yes or
no); comprehensive follow-up. The generation of allocation
sequences was considered adequate if the resulting sequences
were unpredictable (for example, computer-generated random
numbers) and inadequate if the resulting sequences were pre-
dictable (for example, according to case record number). Allo-
cation concealment was considered adequate when the
randomization method used did not allow the investigator or
the participant to identify or influence the intervention group
before enrolment of eligible participants in the study. The
quality of the allocation concealment was considered unclear
when randomization was used but no information about the
method was available and considered inadequate when inap-
propriate methods of randomization were used. Methods for
blinding were considered as double blind (neither patients
nor care providers or assessors knew which intervention was
given), single blind (either patients or care providers or asses-
sors were aware of intervention) and open (all parties were
aware of intervention). In regard to the intention-to-treat anal-
ysis, a positive finding on the reviewers’ part meant that the
authors had specifically reported undertaking this type of anal-
ysis; a negative finding meant that authors did not report the
use of intention-to-treat analysis, that we could not confirm
its use on study assessment, or both. To evaluate the comple-
teness of patient follow-up, we determined the percentage of
participants excluded or lost to follow-up. Completeness of
follow-up was considered to be adequate if $80 % of partici-
pants were included in the final analysis (or assumed to be
adequate when there was no mention of losses to follow-up).
Data extraction. Two reviewers (A. H. and H. S.) inde-
pendently performed data extraction by using standard data-
extraction forms. When important data were not reported or
were unclear, we contacted the corresponding authors of the
primary studies for clarification. Discrepancies between
reviewers were resolved by discussion. For dichotomous out-
comes, we extracted the total number of participants and the
number of participants who experienced the event. For con-
tinuous outcomes, we extracted the total number of partici-
pants and the means and standard deviations. We compared
the extracted data to identify errors. One reviewer (H. S.)
entered the data into REVIEW MANAGER for WINDOWS
software (REVMAN version 4.2; The Cochrane Collaboration,
Oxford, UK) for analysis.
Statistical methods for data analysis
We used the REVMAN for all statistical analyses. The
weighted mean difference between the treatment and control
groups was selected to represent the difference in continuous
outcomes with 95 % CI. The dichotomous outcomes for indi-
vidual studies and pooled statistics are reported as the relative
risk (RR) between the experimental and control groups (with
95 % CI). To pool the data, we used either a fixed-effect or
random-effects model approach, according to the heterogen-
eity in outcomes across studies. Heterogeneity was quantified
by x2 and I 2, which can be interpreted as the percentage of the
total variation between studies that is attributable to hetero-
geneity rather than to chance. A value of 0 % indicates no
observed heterogeneity, and larger values show increasing het-
erogeneity. We took no formal steps to look for publication
bias, such as by plotting effect sizes or by calculating test stat-
istics. In most cases, there are few studies on any given effect,
and any formal method would have had little power.
Description of studies
Initially we identified eight articles. Eventually, only four of
them8 – 11 with 1264 participants met our predefined inclusion
criteria (Table 1). All included studies were fully peer-
reviewed publications. A study by Olsen et al.11 included
six independent randomized clinical trials (four prophylactic
and two therapeutic), and addressed various possible effects
of fish oil supplementation in high-risk pregnancies. The
inclusion criteria of the present review were met by only
three prophylactic trials, which enrolled women after 16
weeks of gestation with an uncomplicated pregnancy but
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with a history of PD (Earl-PD), IUGR (Earl-IUGR), or PIH
(Earl-PIH) in an earlier pregnancy. The remaining three
trials of the Olsen et al. study11 were excluded: one prophylac-
tic trial enrolled women with current twin pregnancies; two
therapeutic trials did not report any useable data by outcomes
of the present review. In addition, four RCT were also
excluded (Table 2). In brief, the studies were excluded
because the population in one trial was the same as reported
in another study12, the type of supplementation was combi-
nation LC-PUFA with another intervention13, and in one
trial investigators included a mixed population of women in
low- and high-risk pregnancies14. Further, one of the initially
included studies15 was eliminated due to its poor methodologi-
cal quality – completeness of follow up in this trial was
inadequate (only 63 % of participants were included in the
final analysis).
Participants
Table 1 summarizes characteristics of women with high-risk
pregnancies. In brief, two studies8,11 included women con-
sidered to be in high-risk pregnancies because (1) they had
an earlier pregnancy PD (Olsen et al. Earl-PD trial11), (2)
had IUGR (Olsen et al. Earl-IUGR trial11 and Bulstra-
Ramakers et al.8), or (3) had PIH (Olsen et al. Earl-PIH11).
Two RCT9,10 included women with a complication in the cur-
rent pregnancy.
Intervention
The sources as well as the doses and duration of LC-PUFA
supplied varied among trials (Table 1). In one trial investi-
gators used primrose oil alone9, in one RCT investigators
reported supplementation with EPA alone8, and in the remain-
ing two studies10,11 investigators used fish oil as a varied com-
bination of EPA with DHA. In the included studies, the daily
dose of DHA was about 900–1080 mg. The trials differed in
the starting time of intervention, beginning as early as from
week 12 of gestation8 to as late as week 30 of gestation9,11.
Methodological quality of the included studies
All four trials used an adequate randomization method and an
adequate method to conceal allocation. All trials were
described as ‘double blinded’. An adequate description of
the intention-to-treat analysis was provided only in three
RCT8,10,11. Withdrawals and dropouts were described ade-
quately in all studies. All trials included an adequate number
of participants in the final analysis (Table 1).
Results
Duration of pregnancy
Based on the results of two RCT8,10, involving 295 partici-
pants, we found no evidence that supplementation influences
the duration of pregnancy .37 weeks of gestation (RR 0·99
(95 % CI 0·9, 1·1)) (Fig. 1). One study reported data on the
duration of pregnancy in days. The results of this trial
showed a significant difference between the supplemented
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(SD 29·5) d, mean difference 8·5 (SD 1·9) d, P¼0·01; Olsen
et al. Earl-PD11).
In addition, the results of the analysis demonstrated no
association of maternal fatty acid intake with risk of PD
,37 weeks of gestation (three RCT8,10,11 involving 523 par-
ticipants; RR 0·82 (95 % CI 0·6, 1·12)). However, when the
effects of supplementation were examined on the rate of
early PD (,34 weeks of gestation), the RR was found to be
reduced in the supplemented group (two RCT8,11 involving
291 participants; RR 0·39 (95 % CI 0·18, 0·84)) (Fig. 1).
Birth weight
In the two RCT involving 494 infants, we found no significant
difference in mean birth weight between supplemented and
non-supplemented control subjects (pooled weighted mean
difference 221·7 (95 % CI 2129·4, 85·9) g; Fig. 2) (Olsen
et al. Earl-PD and Olsen et al. Earl-IUGR11). Data from the
Moodley & Norman study9 were not included in the meta-
analysis. That study presented only the mean, without the stan-
dard deviations of outcomes. However, these data showed no
significant difference in birth weight for those supplemented
compared with control (2·62 (range 1·00–3·05) v. 2·66
(range 1·90–3·25) kg).
There was also no significant difference in the rate of
infants born with low birth weight, defined as birth weight
below the 10th percentile (two RCT8,10 involving 295 infants;
RR 1·03 (95 % CI 0·73, 1·47)), as well as birth weight below
2500 g (two RCT (Olsen et al. Earl-PD and Olsen et al. Earl-
IUGR11); 494 infants; RR 1·03 (95 % CI 0·71, 1·51)) (Fig. 1).
Only one RCT11 reported data on the recurrence of IUGR.
There was no significant difference between supplemented and
non-supplemented subjects (RR 1·17 (95 % CI 0·81, 1·69)).
Other pregnancy outcomes
We found no evidence that supplementation with any LC-
PUFA influences PIH (three RCT8,10,11 involving 645
women; RR 1·06 (95 % CI 0·87, 1·29)). Similarly, there was
no significant difference between groups, when we assessed
proteinuric PIH (two RCT8,10 involving 295 women; RR
0·99 (95 % CI 0·56, 1·74)) and non-proteinuric PIH (two
RCT8,10 involving 295 women; RR 1·20 (95 % CI 0·33,
1·47)). In addition, two RCT8,10 involving 449 women
recorded use of anti-hypertensive therapy. These data did
not differ significantly between supplemented and non-sup-
plemented subjects (RR 0·73 (95 % CI 0·46, 1·15)). Based
on one study (Olsen et al. Earl-PIH), no difference in the
rate of pre-eclampsia was found (one RCT11 involving 321
women; RR 0·72 (95 % CI 0·35, 1·49)). In two RCT8,10
involving 295 participants, no significant difference between
supplemented and non-supplemented women was observed
in the rate of Caesarean delivery (RR 1·30 (95 % CI 0·89,
1·90)). The rate of fetal and/or neonatal death was similar in
both groups (two RCT8,10 involving 295 participants; RR 0·6
(95 % CI 0·15, 2·42)) (Fig. 1).
Heterogeneity
Significant heterogeneity was found for birth weight ,2500 g
(x2 5·15; P¼0·02; I 2 80·6 %). For other outcomes, there was
no heterogeneity.
Adverse events
A narrative synthesis of these data on adverse events was
undertaken. Among four trials included in the review, adverse
effects were reported only in two of them10,11. In the study by
Onwude et al.10 the response rate for the adverse events ques-
tionnaire was only 32 %. The reported side effects between
fish oil and placebo were belching (2·4 v. 0 %), unpleasant
taste (17 v. 5·9 %), nausea (9·7 v. 2·9 %) and stomach pains
(4·8 v. 0 %). With regard to the condition of the child after
delivery, 27 % respondents in the supplemented group and
35 % in the control group reported that the children had suf-
fered minor illness. In addition, there was one case in the sup-
plemented group of staphylococcal septicaemia.
Olsen et al.11 combined all six independent trials into a
single study. They compared the incidence of adverse effects
between supplemented and non-supplemented subjects; separ-
ate data for the individual trials were not reported. These
extracted data showed that the population of women who
reported belching and unpleasant taste was significantly
greater in the fish oil group than in the control group (29·2
v. 8·1 %, and 17·0 v. 2·3 %, respectively). Other complaints
such as nausea, vomiting, diarrhoea, constipation, nose bleed-
ing and vaginal bleeding were equally distributed between the
two groups. There was a possible trend regarding infant intra-
cranial haemorrhage which was greater in the fish oil than the
olive oil group (RR 2·4 (95 % CI 0·6, 11·6); P¼0·22). How-
ever, no differences were observed between both groups in
any of the examined variables, which could reflect other
bleeding complications (such as nose bleeding and vaginal
bleeding leading to hospital admittance).
Discussion
The results of the present analysis indicate that n-3 LC-PUFA
fish oil supplementation during high-risk pregnancy reduced
the risk of early PD (,34 weeks of gestation). However,
Table 2. Characteristics of the excluded studies
Study Study design, purpose, and/or reason(s) for exclusion
D’Almeida et al. (1992)14 Mixed population of healthy pregnant women (79 %) and women with high-risk pregnancies (21 %)
Herrera et al. (1998)13 As a supplementation investigators used a low-dose linoleic acid with a combination of Ca
Laivouri et al. (1993)15 Poor methodological quality; only 63 % of participants included in final analysis
Pavlowich et al. (1999)12 The population was the same as reported in the Olsen study11
Olsen et al. (2000)11 Women with current twin pregnancies
Two therapeutic trials did not report any useable data by outcomes of the present review
A. Horvath et al.256
https://doi.org/10.1017/S0007114507709078
Downloaded from https:/www.cambridge.org/core. IP address: 138.246.2.185, on 03 Mar 2017 at 14:17:24, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
since there was a significant heterogeneity for birth weight
,2500 g and since usually weight correlated with gestational
week, the significant result of a lower incidence of early PD
should be viewed with caution.
The conclusions from the present review apply only to
women whose pregnancies are high-risk pregnancies. As we
demonstrated earlier6, available results from RCT involving
women at low risk of preterm birth indicate that maternal
Fig. 1. Relative risk (RR) and 95 % CI of the pregnancy outcomes in women supplemented with n-3 long-chain PUFA as compared with women who received no
supplementation or placebo. Values for individual trials and pooled data (fixed-effect model) are shown. Earl-PD, preterm delivery in an earlier pregnancy; Earl-
IUGR, intra-uterine growth retardation in an earlier pregnancy; Earl-PIH, pregnancy-induced hypertension in an earlier pregnancy.
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LC-PUFA supplementation is associated with a small incre-
ment in the duration of pregnancy; however, the implications
of this finding for later growth and development are not clear.
The results of the present review, as well as our previous
review,6 are in line with the conclusions of the recent
Cochrane Review16 that concluded there is not enough evi-
dence to support the routine use of marine oil, or other PG pre-
cursor, supplements during pregnancy to reduce the risk of
pre-eclampsia, preterm birth, low birth weight or small for
gestational age.
The present review focused on the effect of LC-PUFA sup-
plementation during high-risk pregnancy on pregnancy out-
comes and infant growth measures. Although it has been
proposed that accretion of n-3 fatty acids has the potential
to improve infants’ neurocognitive development and visual
function,17,18 we did not find any studies which examined
this issue in the population of high-risk pregnancies.
Limitations
We acknowledge several limitations to the present review.
The trials differed considerably in the definition of what con-
stituted high-risk pregnancy, which may be an argument
against combining the results. Unfortunately, sufficient details
to extract data about separate participant types were not avail-
able in the original trials. Thus, the delineation of more
defined populations was not feasible. A further limitation is
that intervention studies used various supplementations (i.e.
primrose oil, EPA, EPA and DHA). This variability may
have introduced a bias in the cumulative data. Nevertheless,
we decided to pool the results together to estimate the
extent to which LC-PUFA supplementation, achieved by a
variety of means, generally has an impact on pregnancy out-
comes and growth measures at birth. Due to a limited
number of studies available, we abstained from subgroup anal-
ysis based on the type of intervention. The sample sizes in
some trials, as well as the number of trials for some compari-
sons (for example, IUGR, or pre-eclampsia), were very small.
The pooled sample sizes were also small, and, thus, there was
little statistical power; consequently, we cannot exclude
chance as an explanation for the results of many comparisons.
In our meta-analysis, the statistical tests of the homogeneity
(total consistency) of the results, with one exception, were
non-significant. However, it is important to stress that the
power of the statistical methods that investigate heterogeneity
is limited, particularly for meta-analyses based on a small
number of studies, as in this case. Consequently, the results
of our meta-analysis, particularly those regarding pregnancy
outcomes, should be viewed with caution.
Our meta-analysis is based on a limited number of studies
and indicated that more studies are needed to address this
topic. Nevertheless, we believe that our demonstration of
clinical uncertainty about this issue is an important finding.
As pointed out by Alderson & Roberts,19 clinical uncertainty
is a prerequisite for the large-scale RCT needed to evaluate
the influence of such interventions; it also helps to clarify
available treatment options and stimulate new and better
research.
Conclusions
Some evidence exists that maternal LC-PUFA supplemen-
tation is associated with a small reduction in risk of early
PD. However, there was no convincing indication of any pro-
phylactic effects of LC-PUFA supplementation on IUGR, PIH
or other pregnancy complications. There is not enough evi-
dence to recommend the routine use of LC-PUFA supplemen-
tation in high-risk pregnancy. Further studies that have larger
sample sizes and that take confounding factors into account
are needed to examine the effects of such supplementation
in high-risk pregnancies.
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